Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines

详细信息    查看全文

• 作者：Estefan&#xed ; a Carrasco-Garc&#xed ; a^a ; ^b ; Miguel Saceda^a ; ^b ; Silvina Grasso^a ; Lourdes Rocamora-Reverte^a ; Mariano Conde^a ; Á ; ngeles Gó ; mez-Mart&#xed ; nez^a ; Pilar Garc&#xed ; a-Morales^a ; ^b ; José ; A. Ferragut^a ; Isabel Mart&#xed ; nez-Lacaci^a ; ^c ; ^{imlacaci@umh.es"" rel=""nofollow} ; ^{misabel.martinezl@carm.es"" rel=""nofollow}
• 关键词：EGFR ; Receptor tyrosine kinase inhibitors ; Cetuximab ; Cell cycle ; Glioblastoma
• 刊名：Experimental Cell Research
• 出版年：2011
• 出版时间：10 June 2011
• 年：2011
• 卷：317
• 期：10
• 页码：1476-1489
• 全文大小：1238 K

文摘

Signaling through the epidermal growth factor receptor (EGFR) is relevant in glioblastoma. We have determined the effects of the EGFR inhibitor AG1478 in glioblastoma cell lines and found that U87 and LN-229 cells were very sensitive to this drug, since their proliferation diminished and underwent a marked G₁ arrest. T98 cells were a little more refractory to growth inhibition and A172 cells did not undergo a G₁ arrest. This G₁ arrest was associated with up-regulation of p27^kip1, whose protein turnover was stabilized. EGFR autophosphorylation was blocked with AG1478 to the same extent in all the cell lines. Other small-molecule EGFR tyrosine kinase inhibitors employed in the clinic, such as gefitinib, erlotinib and lapatinib, were able to abrogate proliferation of glioblastoma cell lines, which underwent a G₁ arrest. However, the EGFR monoclonal antibody, cetuximab had no effect on cell proliferation and consistently, had no effect on cell cycle either. Similarly, cetuximab did not inhibit proliferation of U87 ΔEGFR cells or primary glioblastoma cell cultures, whereas small-molecule EGFR inhibitors did. Activity of downstream signaling molecules of EGFR such as Akt and especially ERK1/2 was interrupted with EGFR tyrosine kinase inhibitors, whereas cetuximab treatment could not sustain this blockade over time. Small-molecule EGFR inhibitors were able to prevent phosphorylation of erbB3 and erbB4, whereas cetuximab only hindered EGFR phosphorylation, suggesting that EGFR tyrosine kinase inhibitors may mediate their anti-proliferative effects through other erbB family members. We can conclude that small-molecule EGFR inhibitors may be a therapeutic approach for the treatment of glioblastoma patients.